Phio Pharmaceuticals Corp.
PHIO evidence brief
What we can confirm
- BioSniper Score:
- 9.8 / 10
- Market Cap:
- $12.0M
What it means
What to watch
Prepared research question
What matters most for PHIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PHIO
Phio Pharmaceuticals Corp. (PHIO) is a clinical-stage siRNA biopharmaceutical company developing cancer therapeutics using its proprietary INTASYL® gene-silencing platform, with its lead candidate PH-762 advancing in cutaneous squamous cell carcinoma trials.
Key risk: Limited cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$12.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Phio Pharmaceuticals Corp. (PHIO) is a clinical-stage siRNA biopharmaceutical company developing cancer therapeutics using its proprietary INTASYL® gene-silencing platform, with its lead candidate PH-762 advancing in cutaneous squamous cell carcinoma trials.
- Lead candidate PH-762 completed Phase 1b dose escalation with favorable safety, tolerability, and pathology data [news · 2026-03-06].
- Phase 1b trial reported a 65% overall response rate for squamous cell carcinomas, with 9 of 20 cSCC patients achieving complete response [sec_mda · as of 2026-08-06].
- Cash & equivalents of $13.0M as of 2026-06-30, with net income of -$4.1M and shareholders' equity of $12.6M [sec].
- Company submitted a meeting request to the FDA to support a planned Phase 2b neoadjuvant study for PH-762 [news · 2026-09-14].
- Production of the first batch of drug substance for PH-762 was initiated in June 2026 to supply the next clinical trial [sec_mda · as of 2026-08-06].
What works
- Phase 1b data showed a 65% overall response rate for cSCC, with 9 of 20 patients achieving complete tumor clearance [sec_mda · as of 2026-08-06].
- No serious adverse events or dose-limiting toxicities were identified across all five dose cohorts in the Phase 1b trial [news · 2026-02-10].
- The company raised $23.7 million in net proceeds from 2025 financings and warrant exercises, extending cash runway into the first half of 2027 [news · 2026-03-06].
What to weigh
- The company reported a net loss of -$4.1M for the period ending 2026-06-30, indicating ongoing operating expenses exceed revenue [sec].
- Cash & equivalents of $13.0M as of 2026-06-30, while extended into H1 2027, still limits the company to a relatively short runway before needing additional financing [sec].
- The Phase 1b trial included only 22 patients, a small sample size that may limit generalizability of efficacy results [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Phase 1b trial results for PH-762
“22 patients with cutaneous carcinomas completed treatment in the Phase 1b trial and underwent excision of the treated lesional site. Reported data supports an overall response rate of 65% for squamous cell carcinomas (cSCC).”
SEC MD&A · August 6, 2026
Safety profile of PH-762
“No Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation Cohorts”
News · February 10, 2026
Cash runway extension
“2025 Financings and Warrant Exercises Strengthen Balance Sheet with $23.7 Million in Net Proceeds, Extending Cash Runway into the First Half of 2027”
News · March 6, 2026
FDA submission for next stage
“Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b Trial”
News · September 14, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $13.0M as of 2026-06-30 extends only into H1 2027, requiring additional financing before then [sec].
- Small Phase 1b sample size — Only 22 patients in Phase 1b, limiting statistical power and generalizability of efficacy claims [sec_mda · as of 2026-08-06].
- No approved products — Company has no marketed products; all revenue is zero, and net loss of -$4.1M reflects pre-commercial stage [sec].
- Regulatory uncertainty for Phase 2b — FDA meeting request submitted but no approval yet for the planned Phase 2b neoadjuvant study [news · 2026-09-14].
What to watch
- FDA response to the meeting request for the planned Phase 2b neoadjuvant study of PH-762 [news · 2026-09-14].
- Initiation and results of the GLP toxicology study for PH-762, started in May 2026 [sec_mda · as of 2026-08-06].
- Company presentations at Life Sciences Future 2026 (Sept 30-Oct 1) and NIBA 153rd Conference (Oct 2026) for clinical updates [news · 2026-09-23][news · 2026-10-05].
- Cash burn rate and any new financing activities as the runway extends into H1 2027 [news · 2026-03-06].
Sources: News · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Phio Pharmaceuticals Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Phio Pharmaceuticals Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.14
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
4 buys · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$749K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 147,254 | $180K |
| jane street group, llc | 119,189 | $145K |
| vanguard capital management llc | 79,853 | $97K |
| cetera investment advisers | 45,000 | $55K |
| vanguard fiduciary trust co | 38,169 | $47K |
| two sigma investments, lp | 32,495 | $40K |
| scientech research llc | 30,032 | $37K |
| ubs group ag | 26,987 | $33K |
| xtx topco ltd | 24,868 | $30K |
| northern trust corp | 23,758 | $29K |
Showing top 10 of 24 institutional holders of Phio Pharmaceuticals Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 4.1%
- Days to cover
- 2.9
- Shares short
- 469,570
- Daily short volume (May 1, 2026)
- 38.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PHIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Phio Pharmaceuticals Corp.?
Phio Pharmaceuticals Corp. (PHIO) is a clinical-stage siRNA biopharmaceutical company developing cancer therapeutics using its proprietary INTASYL® gene-silencing platform, with its lead candidate PH-762 advancing in cutaneous squamous cell carcinoma trials.
Who is the CEO of Phio Pharmaceuticals Corp.?
Mr. Robert J. Bitterman is the chief executive officer of Phio Pharmaceuticals Corp. (PHIO).
Where is Phio Pharmaceuticals Corp. headquartered?
Phio Pharmaceuticals Corp. (PHIO) is headquartered in King of Prussia, PA, United States.
What therapeutic areas does Phio Pharmaceuticals Corp. focus on?
Phio Pharmaceuticals Corp. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.